This is a Notice of Intent, not a request for proposal.  The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Genscript USA Incorporated, 860 Centennial Ave, Piscataway, NJ 08854.

The Laboratory of Immunogenetics (LIG) has been using Genscript CloneArk Plasmid Preparation and HTP Gene to Antibody-Customized Service for this ongoing project, and it has proven to support our protocols in the projects for cellular and molecular mechanisms that underlie the signaling functions in immune cells. These antibodies will be used to design new vaccine candidates and be tested for the ability to prevent SARS-CoV-2 .

Changing provider now will compromise the integrity of our data.

No substitutions are accepted for this project. This is for COVID-19.

The statutory authority for this sole source requirement is 41 U.S.C.1901 (e) (2) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. 

All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2088092) to Skye Duffner at [email protected], by 10:00 am eastern standard time, September 21, 2021.  All responses received by the closing date of this synopsis will be considered by the Government.  A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.